Aims A robust immunohistochemistry (IHC) assay was developed to detect lymphocyte-activation gene 3 (LAG-3) expression by immune cells (ICs) in tumour tissues. LAG-3 is an immuno-oncology target with demonstrable clinical benefit, and there is a need for a standardised, well-characterised assay to measure its expression.

Relatlimab（BMS-986016）是一种抗LAG-3全人源IgG4-κ单克隆抗体，也是临床上开发的首个LAG-3阻断剂。 Relatlimab以高亲和力结合LAG-3并抑制其与MHC-II的结合。 一项重要试验是Ⅲ期 RELATIVITY-047 ，评估了relatlimab+nivolumab vs. nivolumab对未经治疗的转移性或不可切除的 …

2020年5月25日 · LAG-3 IHC expression was confirmed by in situ hybridization (ACD RNAScope). Positivity was defined as at least one LAG-3+ve or PD-1+ve tumor-infiltrating lymphocyte (TIL) per 40x magnification hot spot field (HSF); high LAG-3 expression was defined as …

2023年6月4日 · This study establishes an association between pre-treatment LAG-3, CD8, STAT1, and LAG-3 + CD8 + tissue expression and responsiveness to monoclonal antibody immunotherapy in patients with advanced HCC, with the LAG-3 + CD8 + cell proportion being the most favorable protein biomarker.

2020年4月8日 · LAG3 is found at high levels on CD8 T cells and CD4 Tregs, with almost universal coexpression of PD-1 and TIM3. Blockade of the PD-1 axis has modest efficacy in diffuse large B-cell lymphoma (DLBCL), but data regarding LAG3 are sparse.

2023年12月7日 · LAG3 regulates cancer immunity and is a potential target for ICIs therapy. PD-1 and LAG3 inhibitors may contribute to a better prognosis in MPM.

Aims: A robust immunohistochemistry (IHC) assay was developed to detect lymphocyte-activation gene 3 (LAG-3) expression by immune cells (ICs) in tumour tissues. LAG-3 is an immuno-oncology target with demonstrable clinical benefit, and there is a need for a standardised, well-characterised assay to measure its expression.

2024年12月24日 · Despite the discussed limitations, our study provides an important systematic analysis of the tumor cell intrinsic expression of LAG-3, TIM-3 and their ligands in melanoma metastases in combination with clinical factors and points toward a possible prognostic value of melanoma cell intrinsic LAG-3 expression for anti-PD-1 therapy resistance.

2022年2月25日 · A robust immunohistochemistry (IHC) assay was developed to detect LAG-3 expression by ICs. The assay was used to stratify patients enrolled in RELATIVITY-047, based on the percentage of LAG-3–positive ICs with a morphological resemblance to lymphocytes relative to all nucleated cells within the tumor region (tumor cells [TCs],

LAG3 expression is assessed as the percentage of immune cells with positive staining that had a morphologic resemblance to lymphocytes within the tumor region (consisting of the tumor, intervening stroma, and invasive margin) relative to all nucleated cells in the tumor region in samples containing at least 100 viable tumor cells.